A Phase II Trial of TKI258 in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib(CTKI258AKR01T)
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2014
At a glance
- Drugs Dovitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 13 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2013 Planned end date changed from 1 Mar 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.